Stocks · Healthcare · Biotechnology
EyePoint Pharmaceuticals, Inc. EYPT
$3.25 +0.62% Close, Oct 2, 2026 · NASDAQ · Market cap $272.5M
Weak trendExpensive vs sectorHigh risk
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $2.8M, down 94.6% from a year earlier, slowing from -86.4% a quarter earlier.
- Operating margin narrowed to -11365.2% from -364.3% a year earlier.
- The diluted share count rose 23.8% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 5%
- Revenue growth, 3-year CAGRBottom 12%
- Revenue growth accelerationBottom 20%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 4%
- Gross marginBottom 27%
- Operating marginBottom 3%
- Accruals (lower is better)Top 18%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 4%
- Free-cash-flow yieldBottom 3%
- EBITDA / enterprise valueBottom 2%
- Sales / enterprise valueBottom 11%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 3%
- 6-month returnBottom 1%
- 1-year return vs S&P 500Bottom 1%
- Distance from 52-week highBottom 2%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 27%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 32%
- Upside to consensus price targetTop 5%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 1%
- Maximum drawdown, 3 yearsBottom 18%
- Beta vs S&P 500 (lower is better)Bottom 7%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -86.4% | -94.6% | ↓ |
| Gross margin | 95.1% | 41.8% | ↓ |
| Operating margin | -364.3% | -11365.2% | ↓ |
| FCF margin | -373.9% | -9726.7% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -94.6% | -86.4% | ↓ | Bottom 5% |
| Gross margin | 41.8% | 95.1% | ↓ | Bottom 27% |
| Operating margin | -11365.2% | -364.3% | ↓ | Bottom 3% |
| Net margin | -10994.7% | -337.9% | ↓ | — |
| Free-cash-flow margin | -9726.7% | -373.9% | ↓ | — |
| Return on invested capital | -167.8% | — | Bottom 4% | |
| Revenue growth, 3-year CAGR | -8.8% | — | Bottom 12% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -17.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1262.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +8.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -73.03%
- Shareholder yield
- -73.03%
- Share count change, 1 year
- +23.8%
- Share count change, 3-year CAGR
- +32.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 0 of 8
- Average EPS surprise, last 4
- -11.9%
- Average 2-day reaction, last 8
- -1.5%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $18.29
- Target vs current price
- +462.8%
- Analysts with a rating
- 20
- Share rating Buy or Strong Buy
- 65%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | -7.9% | +5.0% | +11.8% | -60.8% | — |
| May 6, 2026 | -25.3% | -2.9% | -0.9% | -10.3% | -10.9% |
| Mar 4, 2026 | -3.8% | -1.7% | -15.7% | -29.6% | -26.3% |
| Nov 5, 2025 | -10.4% | -11.1% | -6.0% | +17.2% | +7.3% |
| Aug 6, 2025 | -26.9% | -2.8% | -1.3% | +10.2% | +7.7% |
| May 7, 2025 | +0.0% | -2.6% | -5.4% | +31.2% | +55.4% |
| Mar 5, 2025 | -18.5% | +8.2% | +20.9% | -16.9% | +18.6% |
| Nov 7, 2024 | -12.5% | -4.1% | -10.9% | -32.5% | -35.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$1.09 | -$1.01 | -7.9% | $507,000 |
| May 6, 2026 | -$0.99 | -$0.79 | -25.3% | $696,000 |
| Mar 4, 2026 | -$0.81 | -$0.78 | -3.8% | $620,000 |
| Nov 5, 2025 | -$0.85 | -$0.77 | -10.4% | $966,000 |
| Aug 6, 2025 | -$0.85 | -$0.67 | -26.9% | $5.3M |
| May 7, 2025 | -$0.65 | -$0.65 | +0.0% | $24.5M |
| Mar 5, 2025 | -$0.64 | -$0.54 | -18.5% | $11.6M |
| Nov 7, 2024 | -$0.54 | -$0.48 | -12.5% | $10.5M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 66.11× | — | — | Bottom 11% |
| Free-cash-flow yield | -99.56% | — | — | Bottom 3% |
| Earnings yield | -115.08% | — | — | Bottom 4% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -36.0%
- 200-day average slope (20 days)
- -8.3%
- Distance from 50-day average
- -53.7%
- Distance from 200-day average
- -74.1%
- RSI (14)
- 29.4
- Relative volume
- 0.89×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 243.6%
- Volatility vs own 5-year history
- 99th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.32
- Correlation with S&P 500
- 0.39
- Current drawdown from 1-year high
- -82.8%
- Maximum drawdown, 3 years
- -89.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 12, 2024 | Oct 1, 2026 | -89.1% | 661 days | Not yet recovered |
| Nov 17, 2021 | Mar 24, 2023 | -87.6% | 338 days | 177 days (Dec 6, 2023) |
| Feb 17, 2021 | Jul 14, 2021 | -49.7% | 102 days | 82 days (Nov 8, 2021) |
| Sep 25, 2020 | Oct 30, 2020 | -33.9% | 25 days | 39 days (Dec 28, 2020) |
| Dec 27, 2023 | Jan 4, 2024 | -17.4% | 5 days | 12 days (Jan 23, 2024) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $272.5M
- EPS, diluted (TTM)
- -$3.74
- Revenue (TTM)
- $2.8M
- 52-week range
- $3.10 – $19.11
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $36.9M | $41.4M | $46.0M | $43.3M | $31.4M |
| Gross profit | $28.8M | $33.1M | $41.4M | $39.6M | $29.3M |
| Operating income | -$55.3M | -$99.6M | -$75.1M | -$145.9M | -$243.4M |
| Net income | -$58.4M | -$102.3M | -$70.8M | -$130.9M | -$232.0M |
| EPS (diluted) | -$2.03 | -$2.74 | -$1.82 | -$2.32 | -$3.17 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.5M | $11.6M | $24.5M | $5.3M | $966,000 | $620,000 | $696,000 | $507,000 |
| Net income | -$29.4M | -$41.4M | -$45.2M | -$59.4M | -$59.7M | -$67.6M | -$84.8M | -$94.5M |
| EPS (diluted) | -$0.54 | -$0.64 | -$0.65 | -$0.85 | -$0.85 | -$0.81 | -$0.99 | -$1.09 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$50.1M | -$65.0M | $1.9M | -$126.2M | -$240.1M |
| Capital expenditure | -$156,000 | -$2.1M | -$3.5M | -$4.1M | -$3.3M |
| Free cash flow | -$50.3M | -$67.2M | -$1.6M | -$130.3M | -$243.4M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $216.8M | $395,000 | $226.2M | $163.3M | $175.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $180.5M
- Total assets
- $228.2M
- Total liabilities
- $61.8M
- Total debt
- $22.4M
- Net debt
- -$88.1M
- Shareholders’ equity
- $166.4M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 19,809,561
- Days to cover
- 6.43
- Change vs previous report
- +9.4%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Dec 9, 2020
- 1-for-10
- Jun 11, 2008
- 1-for-4